Last reviewed 2026-05-14 · How we verify

GST-HG161

Fujian Cosunter Pharmaceutical Co. Ltd · Phase 1 active Small molecule

GST-HG161 is a Small molecule drug developed by Fujian Cosunter Pharmaceutical Co. Ltd. It is currently in Phase 1 development. Also known as: selected C-MET Inhibitor.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	GST-HG161
Also known as	selected C-MET Inhibitor
Sponsor	Fujian Cosunter Pharmaceutical Co. Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GST-HG161 CI brief — competitive landscape report
GST-HG161 updates RSS · CI watch RSS
Fujian Cosunter Pharmaceutical Co. Ltd portfolio CI

Frequently asked questions about GST-HG161

What is GST-HG161?

GST-HG161 is a Small molecule drug developed by Fujian Cosunter Pharmaceutical Co. Ltd.

Who makes GST-HG161?

GST-HG161 is developed by Fujian Cosunter Pharmaceutical Co. Ltd (see full Fujian Cosunter Pharmaceutical Co. Ltd pipeline at /company/fujian-cosunter-pharmaceutical-co-ltd).

Is GST-HG161 also known as anything else?

GST-HG161 is also known as selected C-MET Inhibitor.

What development phase is GST-HG161 in?

GST-HG161 is in Phase 1.

Manufacturer: Fujian Cosunter Pharmaceutical Co. Ltd — full pipeline
Also known as: selected C-MET Inhibitor

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing